Blackstone Inc. (NYSE:BX) is one of the 10 Best Asset Management Stocks to Buy Right Now.
On March 3, 2026, Blackstone Life Sciences, a specialized life sciences investment platform of Blackstone Inc., entered a $400 million strategic funding agreement with Teva Pharmaceuticals. The agreement aimed at accelerating the clinical development of duvakitug, a monoclonal antibody targeting TL1A. It is currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, following the success of Phase 2b data. Blackstone Inc.’s investment is spread over four years, and the firm will receive regulatory milestones and low single-digit global royalties upon FDA approval. Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, gave the following statement.
Duvakitug has the potential to be a best-in-class therapy in a large and growing space, and the Teva and Sanofi teams are well positioned to develop and commercialize this important medicine.
In a more recent development, on March 5, 2026, Barclays analyst Benjamin Budish reinstated coverage of Blackstone with an Equal Weight rating and a $126 price target. Following a brief restriction period, the firm is covering the stock with unchanged ratings and earnings estimates.
Founded in 1985, Blackstone Inc. is the world’s largest alternative asset manager operating from its headquarters in New York.
READ NEXT: 10 Best Stocks to Buy According to Elliott Investment Management and 10 Best Stocks to Invest in During a Recession
